Cargando…

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Plasma-based next-generation sequencing (NGS) has demonstrated the potential to guide the personalized treatment of non-small cell lung cancer (NSCLC). Inherent differences in mutational genomic profiles of NSCLC exist between Asian and Western populations. However, the published mutational genomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Byoung Chul, Loong, Herbert H. F., Tsai, Chun-Ming, Teo, Man Lung P., Kim, Hye Ryun, Lim, Sun Min, Jain, Suyog, Olsen, Steve, Park, Keunchil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946965/ https://www.ncbi.nlm.nih.gov/pubmed/35323374 http://dx.doi.org/10.3390/curroncol29030174

Ejemplares similares

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
por: Loong, Herbert H., et al.
Publicado: (2022)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
por: Feng, Wei-neng, et al.
Publicado: (2018)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
por: Huang, Chun-Ta, et al.
Publicado: (2023)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
por: Agulnik, Jason S., et al.
Publicado: (2022)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
por: Chang, Huan, et al.
Publicado: (2018)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Sherwood, James L., et al.
Publicado: (2016)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Insights into genomic structure and evolutionary processes of coastal Suaeda species in East Asia using cpDNA, nDNA, and genome-wide SNPs
por: Park, Jong-Soo, et al.
Publicado: (2020)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pnvl0oefb0je8p751grj0p2hl2